07.13.18
Anthony J. Esposito, Jr. has been appointed senior director of Quality Assurance at InClinica. Mr. Esposito will be responsible for establishing and executing all quality processes and strategies across the company.
Mr. Esposito has more than 25 years of experience in the pharmaceutical industry, specifically in global quality assurance and clinical operations. Prior to joining InClinica, he spent 16 years with Janssen Pharmaceutical Research & Development, LLC, where he most recently served as Regional Therapeutic Area Expert responsible for establishing immunology strategies for North and South America, providing direction for successful trial execution, optimizing protocol design and defining efficient regional commitment for the trial. He also has extensive experience in therapeutic areas including immunology, oncology, dermatology, metabolism, CNS, CV, neuroscience and stem cells.
“We are very excited to welcome Anthony to the team,” said James Nolan, chief executive officer at InClinica. “His decades of experience in global quality assurance will greatly benefit InClinica’s clinical trial operations, and how they perform and comply with inspections globally.”
Mr. Esposito has more than 25 years of experience in the pharmaceutical industry, specifically in global quality assurance and clinical operations. Prior to joining InClinica, he spent 16 years with Janssen Pharmaceutical Research & Development, LLC, where he most recently served as Regional Therapeutic Area Expert responsible for establishing immunology strategies for North and South America, providing direction for successful trial execution, optimizing protocol design and defining efficient regional commitment for the trial. He also has extensive experience in therapeutic areas including immunology, oncology, dermatology, metabolism, CNS, CV, neuroscience and stem cells.
“We are very excited to welcome Anthony to the team,” said James Nolan, chief executive officer at InClinica. “His decades of experience in global quality assurance will greatly benefit InClinica’s clinical trial operations, and how they perform and comply with inspections globally.”